Posted by Michael Wonder on 28 Jan 2016
European Commission approves Daklinza (daclatasvir) for the treatment of genotype 1, 3 and 4 chronic hepatitis C patients with HIV co-infection, advanced cirrhosis and post-liver transplant recurrence of HCV
28 January 2016 - Updated label provides additional treatment options for multiple HCV patient populations, including difficult-to-treat patients with decompensated cirrhosis.
For more details, go to: http://news.bms.com/press-release/european-commission-approves-daklinza-daclatasvir-treatment-genotype-1-3-and-4-chronic
